PURPOSE: The activation of SIRT-1 in the kidney has become a new therapeutic target to increase resistance to many causal factors in DN development. Furthermore, antioxidative stress and anti-inflammation are essential to preventing renal fibrosis in DN. Therefore, finding "probiotic products" to treat and prevent DN is necessary. This study aimed to analyze the anti-inflammatory of probiotic dadiah to activate SIRT-1 in inhibiting DN progression.
METHODS: This study is an experimental group designed with a post-test-only control group to observe the effect of dadiah, LAB, and bacteriocin on alloxan-induced nephropathy diabetic rats through two control groups and five intervention groups for eight weeks. The expression of antibodies SIRT-1 and TNF-α was examined using Immunohistochemistry and histopathology of kidney tissue. All data were analyzed using ANOVA test.
RESULTS: The treatment of dadiah, lactic acid bacteria, and bacteriocin showed a higher expression of Sirtuin-1 than the positive control. They also, reduce TNF-α expression varies significantly between treatments. The highest average of interstitial fibrosis in the C + groups was substantially different from all groups, but all treatments showed decreased kidney fibrosis. Although all treatments showed a decrease in interstitial kidney fibrosis found in the control group, the treatment using dadiah showed the highest result.
CONCLUSIONS: Dadiah has the potential to the prevention of fibrosis on kidney tissue of alloxan-induced nephropathy diabetic rats. The findings could be to develop novel treatments for DN that aim to reduce the cascade of oxidative stress and inflammatory signals in kidney tissue.
* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.